Biosimilars and patient safety risk: promoting policy protections in the health delivery system

Bryan A. Liang, Timothy Mackey

DOI: https://doi.org/10.7175/rhc.v3i2.203

Keywords

Biosimilars; Clinical risk; Patient safety; Health delivery system

Full Text

HTML PDF

References

  • Liang B. Regulating Follow-On Biologics. Harv J Legis 2007; 44: 363-471
  • Silverman E. Drug pipeline loses pressure. Manag Care 2010; 19: 23-6
  • Comer B. Biosimilars Spend to Reach $2.5 Bln by 2015. blog.pharmexec.com, 2011. Available at: http://blog.pharmexec.com/2011/05/18/biosimilars-spend-to-reach-2-5-bln-by-2015-ims [last accessed Mar. 27, 2012]
  • Maiese BA, Lee EH, Toscani M. Follow-on biologics & biosimilars literature review: the current landscape and implications of recent healthcare legislation for the U.S. market. SpecialtyPharmaJournal.com, 2011. Available at: http://www.specialtypharmajournal.com/index.php?option=com_content&view=article&id=2816:follow-on-biologics-a-biosimilars-literature-review-the-current-landscape-and-implications-of-recent-healthcare-legislation-for-the-us-market-&catid=425:catbiosimilars&Itemid=845 [last accessed Mar. 8, 2012]
  • Roger SD. Biosimilars: How similar or dissimilar are they? Nephrology 2006; 11: 341-6
  • Statement of Jay P. Siegel, M.D., Johnson & Johnson. Before the Senate Committee on Health,
  • Education, Labor, and Pensions: Follow-on Biologics, 2007 Available at: http://www.help.senate.gov/old_site/Hearings/2007_03_08/Siegel.pdf [last accessed Mar. 12, 2012]
  • Leuenberger-Fisher MR. The road to follow on biologics: are we there yet? Biotech Law Rep 2004; 23: 389-401
  • EuropaBio. Guide to biological medicines: a focus on biosimilar medicines [Internet]. europabio.org. Available at: http://www.europabio.org/sites/default/files/report/guide_to_biological_medicines_a_focus_on_biosimilar_medicines.pdf [last accessed Mar. 12, 2012]
  • Chamberlain P. Immunogenicity of therapeutic proteins. Part 1: Causes and clinical manifestations of immunogenicity. Reg Rev 2002; 5: 5-9
  • Bennett CL, Cournoyer D, Carson KR, et al. Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. Blood 2005; 106: 3343-7
  • Schellekens H, Jiskoot W. Eprex-associated pure red cell aplasia and leachates. Nat Biotechnol 2006; 24: 613-4
  • ISMP. ISMP’s High-Alert Medications List. ismp.org. Available at: http://www.ismp.org/Tools/highAlertMedications.asp [last accessed Mar. 22, 2012]
  • Mackey TK, Liang BA. The global counterfeit drug trade: Patient safety and public health risks. J Pharm Sci 2011; 100: 4571-9
  • Liang BA, Mackey T. Reforming direct-to-consumer advertising. Nat Biotechnol 2011; 29: 397-400
  • Liang BA, Mackey T. Emerging patient safety issues under health care reform: follow-on biologics and immunogenicity. Ther Clin Risk Manag 2011; 7: 489-93

Statistics

Abstract: 965 views
HTML: 207 views
PDF: 159 views

Refbacks

  • There are currently no refbacks.




© SEEd srl